Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 799 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors . Ann Intern Med 2019:1. [Ref.ID 103162]
2. Cita con resumen
McQuaid J. Asthma takes a hard toll on African-Americans. Can precision medicine ease the burden?. STAT Daily Recap 2019:26 de marzo. [Ref.ID 103064]
3.Enlace a cita original Cita con resumen
Chapman KR, Hurst JR, Frent SM, Larbiq M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:1 de agosto. [Ref.ID 102826]
4. Cita con resumen
Busse WW, Bateman ED, Caplan AL, Kelly W, O'Byrne PM, Rabe KF, Chinchilli VM. Combined analysis of asthma safety trials of long-acting ß2-agonists. N Engl J Med 2018;378:2497-505. [Ref.ID 102733]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White M, Lazarus SC, Blake KV, Lang JE, Baker WL. Association of inhaled corticosteroids and long-acting ß-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma. A systematic review and meta-analysis. JAMA 2018;319:10 de abril. [Ref.ID 102671]
7.Enlace a cita original Cita con resumen
Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]
8. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
9.Enlace a cita original Cita con resumen
Wang M-T, Liou J-T, Lin CW, Tsai C-L, Wang Y-H, Hsu Y-J, Lai J-H. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease. A nested case-control study. JAMA Intern Med 2018;178:febrero. [Ref.ID 102529]
10. Cita con resumen
Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-induced dental caries: a disproportionality analysis using data from VigiBase. Drug Saf 2017;40:1249-58. [Ref.ID 102146]
11. Cita con resumen
Anónimo. EMA panel recommends approval of GSK’s triple inhaler to treat COPD. DIA Daily 2017:2. [Ref.ID 102050]
12. Cita con resumen
Fralick M, Avorn J, Kesselheim AS. The price of crossing the border for medications. N Engl J Med 2017;377:311-3. [Ref.ID 101925]
13. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
14. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
15. Cita con resumen
Velzel J, Vlemmix F, Opmeer BC, Molkenboer JFM, Verhoeven CJ, van Pampus MG, Papatsonis DNM, Bais JMJ, Vollebregt KC, van der Esch L, van der Post JAM, Mol BW, Kok M. Atosiban versus fenoterol as a uterine relaxant for external cephalic version: randomised controlled trial. BMJ 2017;356:i6773. [Ref.ID 101398]
16. Cita con resumen
Anónimo. Décongestionnants rhinopharyngés: fibrillations auriculaires. Prescrire 2017;37:24. [Ref.ID 101364]
17.Enlace a cita original Cita con resumen
Anónimo. Indacaterol for chronic obstructive pulmonary disease. Therapeutics Letter 2016:1-2. [Ref.ID 101043]
18. Cita con resumen
Fitzgerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Buse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41. [Ref.ID 100929]
19. Cita con resumen
Bleecker ER, Fitzgerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27. [Ref.ID 100928]
20.
Bush A, Frey U. Safety of long-acting beta-agonists in children with asthma. N Engl J Med 2016;375:889-91. [Ref.ID 100734]
Seleccionar todas
 
 1 a 20 de 799 siguiente >>